Format
Items per page
Sort by

Send to:

Choose Destination

Results: 13

1.

Suicidal behaviors are very rare in antiparkinsonian drug trials.

Teodoro T, Nzwalo H, Correia Guedes L, Coelho M, Rosa MM, Ferreira JJ.

Parkinsonism Relat Disord. 2015 Jun 15. pii: S1353-8020(15)00261-8. doi: 10.1016/j.parkreldis.2015.06.011. [Epub ahead of print] No abstract available.

PMID:
26096798
2.

Substantia nigra neuromelanin magnetic resonance imaging in de novo Parkinson's disease patients.

Reimão S, Pita Lobo P, Neutel D, Correia Guedes L, Coelho M, Rosa MM, Ferreira J, Abreu D, Gonçalves N, Morgado C, Nunes RG, Campos J, Ferreira JJ.

Eur J Neurol. 2015 Mar;22(3):540-6. doi: 10.1111/ene.12613. Epub 2014 Dec 22.

PMID:
25534480
3.

PRKAR1B mutation associated with a new neurodegenerative disorder with unique pathology.

Wong TH, Chiu WZ, Breedveld GJ, Li KW, Verkerk AJ, Hondius D, Hukema RK, Seelaar H, Frick P, Severijnen LA, Lammers GJ, Lebbink JH, van Duinen SG, Kamphorst W, Rozemuller AJ; Netherlands Brain Bank, Bakker EB; International Parkinsonism Genetics Network, Neumann M, Willemsen R, Bonifati V, Smit AB, van Swieten J.

Brain. 2014 May;137(Pt 5):1361-73. doi: 10.1093/brain/awu067. Epub 2014 Apr 9. Erratum in: Brain. 2015 Feb;138(Pt 2):e331.

4.

The V471A polymorphism in autophagy-related gene ATG7 modifies age at onset specifically in Italian Huntington disease patients.

Metzger S, Walter C, Riess O, Roos RA, Nielsen JE, Craufurd D; REGISTRY Investigators of the European Huntington’s Disease Network, Nguyen HP.

PLoS One. 2013 Jul 22;8(7):e68951. doi: 10.1371/journal.pone.0068951. Print 2013.

5.

Suicidal ideation in a European Huntington's disease population.

Hubers AA, van Duijn E, Roos RA, Craufurd D, Rickards H, Bernhard Landwehrmeyer G, van der Mast RC, Giltay EJ; REGISTRY investigators of the European Huntington's Disease Network.

J Affect Disord. 2013 Oct;151(1):248-58. doi: 10.1016/j.jad.2013.06.001. Epub 2013 Jul 20.

6.

Mutation in the SYNJ1 gene associated with autosomal recessive, early-onset Parkinsonism.

Quadri M, Fang M, Picillo M, Olgiati S, Breedveld GJ, Graafland J, Wu B, Xu F, Erro R, Amboni M, Pappatà S, Quarantelli M, Annesi G, Quattrone A, Chien HF, Barbosa ER; International Parkinsonism Genetics Network, Oostra BA, Barone P, Wang J, Bonifati V.

Hum Mutat. 2013 Sep;34(9):1208-15. doi: 10.1002/humu.22373. Epub 2013 Aug 6.

PMID:
23804577
7.

Reliability and minimal detectable change of physical performance measures in individuals with pre-manifest and manifest Huntington disease.

Quinn L, Khalil H, Dawes H, Fritz NE, Kegelmeyer D, Kloos AD, Gillard JW, Busse M; Outcome Measures Subgroup of the European Huntington's Disease Network.

Phys Ther. 2013 Jul;93(7):942-56. doi: 10.2522/ptj.20130032. Epub 2013 Mar 21.

8.

β-Defensin genomic copy number does not influence the age of onset in Huntington's Disease.

Vittori A, Orth M, Roos RA, Outeiro TF, Giorgini F, Hollox EJ; Registry investigators of the European Huntington's Disease Network.

J Huntingtons Dis. 2013;2(1):107-24. doi: 10.3233/JHD-130002.

PMID:
25057107
9.

Discrepancies in reporting the CAG repeat lengths for Huntington's disease.

Quarrell OW, Handley O, O'Donovan K, Dumoulin C, Ramos-Arroyo M, Biunno I, Bauer P, Kline M, Landwehrmeyer GB; European Huntington’s Disease Network.

Eur J Hum Genet. 2012 Jan;20(1):20-6. doi: 10.1038/ejhg.2011.136. Epub 2011 Aug 3.

10.

Worldwide frequency of G2019S LRRK2 mutation in Parkinson's disease: a systematic review.

Correia Guedes L, Ferreira JJ, Rosa MM, Coelho M, Bonifati V, Sampaio C.

Parkinsonism Relat Disord. 2010 May;16(4):237-42. doi: 10.1016/j.parkreldis.2009.11.004. Epub 2009 Nov 30. Review.

PMID:
19945904
11.

FBXO7 mutations cause autosomal recessive, early-onset parkinsonian-pyramidal syndrome.

Di Fonzo A, Dekker MC, Montagna P, Baruzzi A, Yonova EH, Correia Guedes L, Szczerbinska A, Zhao T, Dubbel-Hulsman LO, Wouters CH, de Graaff E, Oyen WJ, Simons EJ, Breedveld GJ, Oostra BA, Horstink MW, Bonifati V.

Neurology. 2009 Jan 20;72(3):240-5. doi: 10.1212/01.wnl.0000338144.10967.2b. Epub 2008 Nov 26.

PMID:
19038853
12.

Phenotype, genotype, and worldwide genetic penetrance of LRRK2-associated Parkinson's disease: a case-control study.

Healy DG, Falchi M, O'Sullivan SS, Bonifati V, Durr A, Bressman S, Brice A, Aasly J, Zabetian CP, Goldwurm S, Ferreira JJ, Tolosa E, Kay DM, Klein C, Williams DR, Marras C, Lang AE, Wszolek ZK, Berciano J, Schapira AH, Lynch T, Bhatia KP, Gasser T, Lees AJ, Wood NW; International LRRK2 Consortium.

Lancet Neurol. 2008 Jul;7(7):583-90. doi: 10.1016/S1474-4422(08)70117-0. Epub 2008 Jun 6.

13.

Effects of nebicapone on levodopa pharmacokinetics, catechol-O-methyltransferase activity, and motor fluctuations in patients with Parkinson disease.

Ferreira JJ, Almeida L, Cunha L, Ticmeanu M, Rosa MM, Januário C, Mitu CE, Coelho M, Correia-Guedes L, Morgadinho A, Nunes T, Wright LC, Falcão A, Sampaio C, Soares-da-Silva P.

Clin Neuropharmacol. 2008 Jan-Feb;31(1):2-18. doi: 10.1097/wnf.0b013e3180645cb0.

PMID:
18303486
Format
Items per page
Sort by

Send to:

Choose Destination

Supplemental Content

Loading ...
Write to the Help Desk